{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/45586"},"canonical_url":"https://search.ndltd.org/etd/bu/oai:open.bu.edu:2144/45586","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"The emergence of bispecific antibodies as novel cancer therapeutics","abstract":"Bispecific antibodies have recently taken the immune-oncology field by storm through its multi-targeting capabilities and unique mechanisms of action. In the past few decades, this therapeutic format has seen an exponential rise, and with every year, new variations of the basic bispecific concept emerge to precipitate new effects. These effects include cell-to-cell binding, enhanced agonism or antagonism, and target internalization. One of the most promising applications for bispecific antibodies is as a bispecific T-cell engager, which can induce inflammatory responses in previously immune-excluded tumors. This paper aims to provide a high-level overview of the functionality, formats, and clinical results of bispecific antibodies and place them in the context of current treatments for cancer.","abstract_html":"Bispecific antibodies have recently taken the immune-oncology field by storm through its multi-targeting capabilities and unique mechanisms of action. In the past few decades, this therapeutic format has seen an exponential rise, and with every year, new variations of the basic bispecific concept emerge to precipitate new effects. These effects include cell-to-cell binding, enhanced agonism or antagonism, and target internalization. One of the most promising applications for bispecific antibodies is as a bispecific T-cell engager, which can induce inflammatory responses in previously immune-excluded tumors. This paper aims to provide a high-level overview of the functionality, formats, and clinical results of bispecific antibodies and place them in the context of current treatments for cancer.","abstract_has_math":false,"creators":["Li, Robert"],"institution":"Boston University","degree_name":"Master of Science","degree_level":"masters","degree_discipline":"Medical Sciences","degree_department":null,"school":null,"contributors":[],"advisors":["Trinkaus-Randall, Vickery E.","Qin, Yan"],"committee_chairs":[],"committee_members":[],"year":2022,"date_issued":"2022","date_published":"2022","updated_at":"2026-11-18T20:24:00Z","subjects":["Oncology"],"languages":["en_US"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/2144/45586","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/2144/45586","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.bu.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aopen.bu.edu%3A2144%2F45586","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Trinkaus-Randall, Vickery E.","Qin, Yan"]},{"key":"dc:creator","label":"Author","values":["Li, Robert"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2023-02-10T15:04:15Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2023-02-10T15:04:15Z"]},{"key":"dc:date.issued","label":"Date","values":["2022"]},{"key":"dc:date.updated","label":"Dc Date Updated","values":["2023-02-07T02:20:03Z"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Medical Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["masters"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Boston University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Oncology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/45586"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Bispecific antibodies have recently taken the immune-oncology field by storm through its multi-targeting capabilities and unique mechanisms of action. In the past few decades, this therapeutic format has seen an exponential rise, and with every year, new variations of the basic bispecific concept emerge to precipitate new effects. These effects include cell-to-cell binding, enhanced agonism or antagonism, and target internalization. One of the most promising applications for bispecific antibodies is as a bispecific T-cell engager, which can induce inflammatory responses in previously immune-excluded tumors. This paper aims to provide a high-level overview of the functionality, formats, and clinical results of bispecific antibodies and place them in the context of current treatments for cancer."]},{"key":"dc:title","label":"Title","values":["The emergence of bispecific antibodies as novel cancer therapeutics"]}]}],"canonical_facts":{"dc:contributor.advisor":["Trinkaus-Randall, Vickery E.","Qin, Yan"],"dc:creator":["Li, Robert"],"dc:date.accessioned":["2023-02-10T15:04:15Z"],"dc:date.available":["2023-02-10T15:04:15Z"],"dc:date.issued":["2022"],"dc:date.updated":["2023-02-07T02:20:03Z"],"dc:description.abstract":["Bispecific antibodies have recently taken the immune-oncology field by storm through its multi-targeting capabilities and unique mechanisms of action. In the past few decades, this therapeutic format has seen an exponential rise, and with every year, new variations of the basic bispecific concept emerge to precipitate new effects. These effects include cell-to-cell binding, enhanced agonism or antagonism, and target internalization. One of the most promising applications for bispecific antibodies is as a bispecific T-cell engager, which can induce inflammatory responses in previously immune-excluded tumors. This paper aims to provide a high-level overview of the functionality, formats, and clinical results of bispecific antibodies and place them in the context of current treatments for cancer."],"dc:identifier.uri":["https://hdl.handle.net/2144/45586"],"dc:language.iso":["en_US"],"dc:subject":["Oncology"],"dc:title":["The emergence of bispecific antibodies as novel cancer therapeutics"],"dc:type":["Thesis/Dissertation"],"thesis:degree_discipline":["Medical Sciences"],"thesis:degree_level":["masters"],"thesis:degree_name":["Master of Science"],"thesis:institution_name":["Boston University"]},"updated_at":"2026-11-18T20:24:00Z"}